Related Experiment Videos
Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety
Clinical Therapeutics
|April 2, 1998
Summary
Risperidone demonstrates superior efficacy for chronic schizophrenia compared to haloperidol, leading to higher response rates and reduced treatment dropout. This antipsychotic offers a better safety profile with fewer extrapyramidal symptoms.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Trials
Background:
- Haloperidol serves as a benchmark in antipsychotic treatment.
- Comparative trials suggest risperidone offers greater efficacy and fewer extrapyramidal symptoms (EPS) than haloperidol for chronic schizophrenia.
Purpose of the Study:
- To compare the efficacy and safety of risperidone versus haloperidol in patients with chronic schizophrenia.
- To analyze differences in clinical response rates, anticholinergic medication use, and treatment dropout.
Main Methods:
- A meta-analysis of randomized, double-masked, comparative trials using the DerSimonian and Laird random-effects model.
- Inclusion criteria required treatment duration of at least 4 weeks at recommended doses.
Main Results:
- Risperidone therapy was associated with significantly higher clinical response rates compared to haloperidol.
- Significantly less anticholinergic medication was prescribed, and treatment dropout rates were significantly lower with risperidone.
- The findings suggest a lower incidence of EPS and improved treatment compliance with risperidone.
Conclusions:
- Risperidone demonstrates superior efficacy and tolerability over haloperidol for treating chronic schizophrenia.
- These findings support risperidone as a preferred treatment option, offering improved patient outcomes and compliance.